Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease

References

• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020.
   Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53:1900164. doi:10.1183/13993003.00164-2019
   PubMed Web of Science ®Google Scholar
• Celli BR, Wedzicha JA, Drazen JM. Update on clinical aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med. 2019;381:1257–1266. doi:10.1056/NEJMra1900500
   PubMed Web of Science ®Google Scholar
• Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol. 2006;117:18–24; quiz 5. doi:10.1016/j.jaci.2005.11.012
   Web of Science ®Google Scholar
• Ejiofor S, Turner AM. Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med. 2013;7:17–34. doi:10.4137/CCRPM.S7211
   PubMedGoogle Scholar
• Billington CK, Penn RB, Hall IP. β(2) Agonists. Handb Exp Pharmacol. 2017;237:23–40.
   PubMedGoogle Scholar
• Beeh KM, Beier J. The short, the long and the “ultra-long”: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther. 2010;27:150–159. doi:10.1007/s12325-010-0017-6
   PubMed Web of Science ®Google Scholar
• Malerba M, Radaeli A, Montuschi P, Babu KS, Morjaria JB. Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2017;26:319–329. doi:10.1080/13543784.2017.1287172
   PubMed Web of Science ®Google Scholar
• Sidhaye VK, Nishida K, Martinez FJ. Precision medicine in COPD: where are we and where do we need to go? Eur Respir Rev. 2018;27:180022. doi:10.1183/16000617.0022-2018
   PubMed Web of Science ®Google Scholar
• Corlateanu A, Mendez Y, Wang Y, Garnica RJA, Botnaru V, Siafakas N. Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art. Pulmonology. 2020;26:95–100. doi:10.1016/j.pulmoe.2019.10.006
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Coppola A, et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respir Med. 2017;124:6–14. doi:10.1016/j.rmed.2017.01.006
   PubMed Web of Science ®Google Scholar
• Mahon J, Fitzgerald A, Glanville J, et al. Misuse and/or treatment delivery failure of inhalers among patients with asthma or COPD: a review and recommendations for the conduct of future research. Respir Med. 2017;129:98–116. doi:10.1016/j.rmed.2017.05.004
   PubMed Web of Science ®Google Scholar
• Burkes RM, Donohue JF. An update on the global initiative for Chronic Obstructive Lung Disease 2017 guidelines with a focus on classification and management of stable COPD. Respir Care. 2018;63:749–758. doi:10.4187/respcare.06174
   Web of Science ®Google Scholar
• Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;Cd010177.
   Google Scholar
• Zafar MA, Droege C, Foertsch M, Panos RJ. Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2014;23:1687–1701. doi:10.1517/13543784.2014.942730
   PubMed Web of Science ®Google Scholar
• Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther. 2007;20:740–749. doi:10.1016/j.pupt.2006.09.001
   PubMed Web of Science ®Google Scholar
• Murphy L, Rennard S, Donohue J, et al. Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD. Drugs. 2014;74:1635–1657. doi:10.1007/s40265-014-0284-7
   PubMed Web of Science ®Google Scholar
• Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med. 2013;13:26. doi:10.1186/1471-2466-13-26
   PubMed Web of Science ®Google Scholar
• Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;1:Cd010139.
   PubMedGoogle Scholar
• Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. Copd. 2012;9:629–636. doi:10.3109/15412555.2012.729623
   PubMedGoogle Scholar
• Donohue JF, Betts KA, Du EX, et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:367–381. doi:10.2147/COPD.S119908
   PubMed Web of Science ®Google Scholar
• Scott DA, Woods B, Thompson JC, et al. Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Pulm Med. 2015;15:145. doi:10.1186/s12890-015-0138-4
   PubMed Web of Science ®Google Scholar
• Metaxas EI, Balis E. The safety of indacaterol for the treatment of COPD. Expert Opin Drug Saf. 2018;17:637–642. doi:10.1080/14740338.2018.1472233
   PubMed Web of Science ®Google Scholar
• Muro S, Yoshisue H, Kostikas K, Olsson P, Gupta P, Wedzicha JA. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: a pooled analysis. Respirology (Carlton, Vic). 2020;25:393–400. doi:10.1111/resp.13651
   Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234. doi:10.1056/NEJMoa1516385
   PubMed Web of Science ®Google Scholar
• Anzueto AR, Kostikas K, Mezzi K, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respir Res. 2018;19:121. doi:10.1186/s12931-018-0830-z
   PubMed Web of Science ®Google Scholar
• Kalberg C, O’Dell D, Galkin D, Newlands A, Fahy WA. Dual bronchodilator therapy with umeclidinium/vilanterol versus tiotropium plus indacaterol in Chronic Obstructive Pulmonary Disease: a randomized controlled trial. Drugs R D. 2016;16:217–227. doi:10.1007/s40268-016-0131-2
   PubMedGoogle Scholar
• Frampton JE. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014;74:465–488.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with Chronic Obstructive Pulmonary Disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198:329–339. doi:10.1164/rccm.201803-0405OC
   PubMed Web of Science ®Google Scholar
• Bouyssou T, Hoenke C, Rudolf K, et al. Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett. 2010;20:1410–1414. doi:10.1016/j.bmcl.2009.12.087
   PubMed Web of Science ®Google Scholar
• Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334:53–62.
   PubMed Web of Science ®Google Scholar
• van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24:666–672. doi:10.1016/j.pupt.2011.07.006
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629–645. doi:10.2147/COPD.S61717
   PubMed Web of Science ®Google Scholar
• Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697–714. doi:10.2147/COPD.S62502
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s respiratory questionnaire. Am Rev Respir Dis. 1992;145:1321–1327. doi:10.1164/ajrccm/145.6.1321
   PubMed Web of Science ®Google Scholar
• Ramadan WH, Kabbara WK, Abilmona RM. Olodaterol for the treatment of chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2016;73:1135–1143. doi:10.2146/ajhp150364
   Web of Science ®Google Scholar
• Blair HA. Tiotropium/olodaterol: a review in COPD. Drugs. 2019;79:997–1008. doi:10.1007/s40265-019-01133-w
   PubMed Web of Science ®Google Scholar
• Derom E, Brusselle GG, Joos GF. The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects. Ther Adv Respir Dis. 2019;13:1753466619843426. doi:10.1177/1753466619843426
   Web of Science ®Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45:969–979. doi:10.1183/09031936.00136014
   PubMed Web of Science ®Google Scholar
• Procopiou PA, Barrett VJ, Bevan NJ, et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010;53:4522–4530. doi:10.1021/jm100326d
   PubMed Web of Science ®Google Scholar
• Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344:218–230. doi:10.1124/jpet.112.198481
   PubMed Web of Science ®Google Scholar
• Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26:256–264. doi:10.1016/j.pupt.2012.12.001
   PubMed Web of Science ®Google Scholar
• Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142:119–127. doi:10.1378/chest.11-2231
   PubMed Web of Science ®Google Scholar
• Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis. 2013;7:311–319. doi:10.1177/1753465813499789
   PubMed Web of Science ®Google Scholar
• Malerba M, Morjaria JB, Radaeli A. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD–role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2014;9:687–695. doi:10.2147/COPD.S47792
   PubMed Web of Science ®Google Scholar
• Albertson TE, Harper R, Murin S, Sandrock C. Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol. Patient Prefer Adherence. 2015;9:235–242. doi:10.2147/PPA.S71535
   PubMed Web of Science ®Google Scholar
• Siler TM, Donald AC, O’Dell D, Church A, Fahy WA. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62. 5/25μg on health-related quality of life in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:971–979. doi:10.2147/COPD.S102962
   PubMed Web of Science ®Google Scholar
• Donohue JF, Singh D, Munzu C, Kilbride S, Church A. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials. Respir Med. 2016;112:65–74. doi:10.1016/j.rmed.2016.01.001
   PubMed Web of Science ®Google Scholar
• Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic Chronic Obstructive Pulmonary Disease: a randomized study. Adv Ther. 2017;34:2518–2533. doi:10.1007/s12325-017-0626-4
   PubMed Web of Science ®Google Scholar
• Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD. Respir Med. 2017;123:8–17. doi:10.1016/j.rmed.2016.12.001
   PubMed Web of Science ®Google Scholar
• Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Clin Ther. 2012;34:1655–66.e5. doi:10.1016/j.clinthera.2012.06.005
   PubMed Web of Science ®Google Scholar
• Lötvall J, Bakke PS, Bjermer L, et al. Efficacy and safety of 4 weeks’ treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open. 2012;2:e000370. doi:10.1136/bmjopen-2011-000370
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1:210–223. doi:10.1016/S2213-2600(13)70040-7
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–1826. doi:10.1016/S0140-6736(16)30069-1
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Tabberer M, Lomas DA, Birk R, et al. Once-daily triple therapy in patients with COPD: patient-reported symptoms and quality of life. Adv Ther. 2018;35:56–71. doi:10.1007/s12325-017-0650-4
   PubMed Web of Science ®Google Scholar
• Pascual S, Feimer J, De Soyza A, et al. Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study. NPJ Prim Care Respir Med. 2015;25:15018. doi:10.1038/npjpcrm.2015.18
   PubMed Web of Science ®Google Scholar
• Dalby R, Spallek M, Voshaar T. A review of the development of respimat soft mist inhaler. Int J Pharm. 2004;283:1–9. doi:10.1016/j.ijpharm.2004.06.018
   PubMed Web of Science ®Google Scholar
• Skolnik NS, Nguyen TS, Shrestha A, Ray R, Corbridge TC, Brunton SA. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β(2)-agonist bronchodilators. Postgrad Med. 2020;132:198–205. doi:10.1080/00325481.2019.1702834
   PubMed Web of Science ®Google Scholar
• Ge X, Woo AY, Xing G, et al. Synthesis and biological evaluation of β(2)-adrenoceptor agonists bearing the 2-amino-2-phenylethanol scaffold. Eur J Med Chem. 2018;152:424–435. doi:10.1016/j.ejmech.2018.04.041
   PubMed Web of Science ®Google Scholar
• Gan LL, Wang MW, Cheng MS, Pan L. Trachea relaxing effects and beta2-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits. Biol Pharm Bull. 2003;26:323–328. doi:10.1248/bpb.26.323
   PubMed Web of Science ®Google Scholar
• Hao Z, Zhang Y, Pan L, et al. Comparison of enantiomers of SPFF, a novel beta2-Adrenoceptor agonist, in bronchodilating effect in guinea pigs. Biol Pharm Bull. 2008;31:866–872. doi:10.1248/bpb.31.866
   PubMed Web of Science ®Google Scholar
• Pan H, Li Q, Pan L, et al. Stereoselective activity of 2-(4-amino-3-chloro-5- trifluomethyl-phenyl)-2-tert-butylamino-ethanol hydrochloride to improve the pulmonary function in asthma. Biomedical Rep. 2014;2:539–544. doi:10.3892/br.2014.279
   Google Scholar
• Aparici M, Gómez-Angelats M, Vilella D, et al. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. J Pharmacol Exp Ther. 2012;342:497–509. doi:10.1124/jpet.112.193284
   PubMed Web of Science ®Google Scholar
• Beier J, Fuhr R, Massana E, et al. Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma. Respir Med. 2014;108:1424–1429. doi:10.1016/j.rmed.2014.08.005
   PubMed Web of Science ®Google Scholar
• Singh DPR, Ribera A, Seoane B, Messana E, Astbury C. Efficacy and Safety of Abediterol (LAS100977) in Stable Asthma: Phase II, Randomized, Crossover Study. ERS Annual Congress; 2013.
   Google Scholar
• Beier J, Pujol H, Seoane B, et al. Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD. BMC Pulm Med. 2016;16:102. doi:10.1186/s12890-016-0266-5
   PubMed Web of Science ®Google Scholar
• Beier J, Fuhr R, Seoane B, et al. Efficacy, safety, and tolerability of once-daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7-day, crossover study. Pharmacol Res Perspect. 2017;5:e00356. doi:10.1002/prp2.356
   Web of Science ®Google Scholar
• Jacobsen JR, Choi SK, Combs J, et al. A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD. Bioorg Med Chem Lett. 2012;22:1213–1218. doi:10.1016/j.bmcl.2011.11.072
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005;14:775–783. doi:10.1517/13543784.14.7.775
   PubMed Web of Science ®Google Scholar
• Matera MG, Cazzola M. ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs. 2007;67:503–515. doi:10.2165/00003495-200767040-00002
   PubMed Web of Science ®Google Scholar
• Jacobsen JR, Aggen JB, Church TJ, et al. Multivalent design of long-acting β(2)-adrenoceptor agonists incorporating biarylamines. Bioorg Med Chem Lett. 2014;24:2625–2630. doi:10.1016/j.bmcl.2014.04.069
   Web of Science ®Google Scholar
• McKinnell RM, Klein U, Linsell MS, et al. Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD. Bioorg Med Chem Lett. 2014;24:2871–2876. doi:10.1016/j.bmcl.2014.04.095
   Web of Science ®Google Scholar
• Glossop PA, Lane CA, Price DA, et al. Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem. 2010;53:6640–6652. doi:10.1021/jm1005989
   PubMed Web of Science ®Google Scholar
• Macintyre FJI, Surujbally B. A randomised, double-blind study to determine the duration of action of lung pharmacodynamics by plethysmography (sGaw) of a β2 adrenoreceptor agonist, PF-00610355 [abstract]. Eur Respir J. 2009.
   Google Scholar
• GL MF L, Surujbally B, Chong CL, Davis J. Safety and toleration of PF-00610355, a novel inhaled long acting β2 adrenoreceptor agonist [abstract]. Eur Respir J. 2009.
   Google Scholar
• Diderichsen PM, Cox E, Martin SW, Cleton A, Ribbing J. Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2013;76:752–762. doi:10.1111/bcp.12080
   PubMed Web of Science ®Google Scholar
• Stocks MJ, Alcaraz L, Bailey A, et al. Discovery of AZD3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action. ACS Med Chem Lett. 2014;5:416–421. doi:10.1021/ml4005232
   PubMed Web of Science ®Google Scholar
• Bjermer L, Kuna P, Jorup C, Bengtsson T, Rosenborg J. Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA). Drug Des Devel Ther. 2015;9:753–762. doi:10.2147/DDDT.S66049
   PubMed Web of Science ®Google Scholar
• Bjermer L, Rosenborg J, Bengtsson T, Lötvall J. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma. Ther Adv Respir Dis. 2013;7:264–271. doi:10.1177/1753465813497527
   Web of Science ®Google Scholar
• Kuna P, Ivanov Y, Trofimov VI, et al. Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study. Respir Res. 2013;14:64. doi:10.1186/1465-9921-14-64
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008;155:291–299. doi:10.1038/bjp.2008.284
   PubMed Web of Science ®Google Scholar
• Kikkawa H, Kanno K, Ikezawa K. TA-2005, a novel, long-acting, and selective beta 2-adrenoceptor agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other beta 2-agonists. Biol Pharm Bull. 1994;17:1047–1052. doi:10.1248/bpb.17.1047
   PubMed Web of Science ®Google Scholar
• Voss HP, Donnell D, Bast A. Atypical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005. Eur J Pharmacol. 1992;227:403–409. doi:10.1016/0922-4106(92)90158-R
   PubMed Web of Science ®Google Scholar
• Kikkawa H, Naito K, Ikezawa K. Tracheal relaxing effects and beta 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea pig tissues. Jpn J Pharmacol. 1991;57:175–185. doi:10.1254/jjp.57.175
   PubMedGoogle Scholar
• Kikkawa H, Isogaya M, Nagao T, Kurose H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. Mol Pharmacol. 1998;53:128–134. doi:10.1124/mol.53.1.128
   PubMed Web of Science ®Google Scholar
• Voss HP, Shukrula S, Wu TS, Donnell D, Bast A. A functional beta-2 adrenoceptor-mediated chronotropic response in isolated guinea pig heart tissue: selectivity of the potent beta-2 adrenoceptor agonist TA 2005. J Pharmacol Exp Ther. 1994;271:386–389.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149. doi:10.1186/1465-9921-11-149
   PubMed Web of Science ®Google Scholar
• Kottakis INA, Raptis H, Savu A, Linberg SE, Woodcock AA. Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma. Eur Respir J. 2006.
   Google Scholar
• Nandeuil AKI, Raptis H, Roslan H, Ivanov Y, Woodcock A. Safety and tolerability of the novel very long acting β2- agonist carmoterol given as a 2 mg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma. Eur Respir J. 2006.
   Google Scholar
• Chiesi. Annual report 2010. Chiesi Farmaceutici SpA Source document no longer available. 2010
   Google Scholar
• Xing G, Pan L, Yi C, et al. Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent β(2)-adrenoceptor agonists. Bioorg Med Chem. 2019;27:2306–2314. doi:10.1016/j.bmc.2018.10.043
   Web of Science ®Google Scholar
• Woo AY, Ge XY, Pan L, et al. Discovery of β-arrestin-biased β(2)-adrenoceptor agonists from 2-amino-2-phenylethanol derivatives. Acta Pharmacol Sin. 2019;40:1095–1105. doi:10.1038/s41401-018-0200-x
   Web of Science ®Google Scholar
• Yi C, Xing G, Wang S, et al. Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β(2)-adrenoceptor agonists. Bioorg Med Chem. 2020;28:115178.
   Web of Science ®Google Scholar
• Eichel K, von Zastrow M. Subcellular organization of GPCR signaling. Trends Pharmacol Sci. 2018;39:200–208. doi:10.1016/j.tips.2017.11.009
   PubMed Web of Science ®Google Scholar
• Tian X, Kang DS, Benovic JL. β-arrestins and G protein-coupled receptor trafficking. Handb Exp Pharmacol. 2014;219:173–186.
   PubMedGoogle Scholar
• Jean-Charles PY, Kaur S, Shenoy SK. G protein-coupled receptor signaling through β-arrestin-dependent mechanisms. J Cardiovasc Pharmacol. 2017;70:142–158. doi:10.1097/FJC.0000000000000482
   PubMed Web of Science ®Google Scholar
• Kume H. [Role of bronchodilators in therapy for COPD-mechanisms of LABA and LAMA on airway smooth muscle]. Nihon Rinsho. 2016;74:813–819. Japanese.
   Google Scholar
• Cazzola M, Calzetta L, Puxeddu E, et al. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir Res. 2016;17:70.
   PubMed Web of Science ®Google Scholar
• Hughes AD, Chin KH, Dunham SL, et al. Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules. Bioorg Med Chem Lett. 2011;21:1354–1358. doi:10.1016/j.bmcl.2011.01.043
   PubMed Web of Science ®Google Scholar
• Hegde SS, Hughes AD, Chen Y, et al. Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties. J Pharmacol Exp Ther. 2014;351:190–199. doi:10.1124/jpet.114.216861
   PubMed Web of Science ®Google Scholar
• Ambery CL, Wielders P, Ludwig-Sengpiel A, Chan R, Riley JH. Population pharmacokinetics and pharmacodynamics of GSK961081 (batefenterol), a muscarinic antagonist and β2-agonist, in moderate-to-severe COPD patients: substudy of a randomized trial. Drugs R D. 2015;15:281–291. doi:10.1007/s40268-015-0104-x
   PubMedGoogle Scholar
• Bateman ED, Kornmann O, Ambery C, Norris V. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther. 2013;26:581–587. doi:10.1016/j.pupt.2013.03.015
   PubMed Web of Science ®Google Scholar
• Crim C, Watkins ML, Bateman ED, et al. Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:615–629. doi:10.2147/COPD.S190603
   PubMed Web of Science ®Google Scholar
• Wielders PL, Ludwig-Sengpiel A, Locantore N, Baggen S, Chan R, Riley JH. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J. 2013;42:972–981. doi:10.1183/09031936.00165712
   PubMed Web of Science ®Google Scholar
• Norris V, Ambery C. Use of propranolol blockade to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy volunteers: results from two randomized trials. Drugs R D. 2014;14:241–251. doi:10.1007/s40268-014-0060-x
   PubMedGoogle Scholar
• Norris V, Ambery C. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD. Pulm Pharmacol Ther. 2013;26:574–580. doi:10.1016/j.pupt.2013.03.009
   PubMed Web of Science ®Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of Chronic Obstructive Pulmonary Disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460. doi:10.2147/COPD.S234942
   PubMed Web of Science ®Google Scholar
• Riley CM, Sciurba FC. Diagnosis and outpatient management of Chronic Obstructive Pulmonary Disease: a review. JAMA. 2019;321:786–797. doi:10.1001/jama.2019.0131
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. doi:10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163–2196. doi:10.1016/S0140-6736(12)61729-2
   PubMed Web of Science ®Google Scholar
• Siafakas N, Corlateanu A, Fouka E. Phenotyping before starting treatment in COPD? Copd. 2017;14:367–374. doi:10.1080/15412555.2017.1303041
   Google Scholar
• Gonηalves I, Guimarγes MJ, van Zeller M, Menezes F, Moita J, Simγo P. Clinical and molecular markers in COPD. Pulmonology. 2018;24:250–259. doi:10.1016/j.pulmoe.2018.02.005
   Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluρa JJ, Calle M, Soriano JB. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J. 2013;41:1252–1256. doi:10.1183/09031936.00118912
   PubMed Web of Science ®Google Scholar
• Le Rouzic O, Roche N, Cortot AB, et al. Defining the “frequent exacerbator” phenotype in COPD: a hypothesis-free approach. Chest. 2018;153:1106–1115. doi:10.1016/j.chest.2017.10.009
   PubMed Web of Science ®Google Scholar
• Blasi F, Neri L, Centanni S, Falcone F, Di Maria G. Clinical characterization and treatment patterns for the frequent exacerbator phenotype in Chronic Obstructive Pulmonary Disease with severe or very severe airflow limitation. Copd. 2017;14:15–22. doi:10.1080/15412555.2016.1232380
   Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Singh D, Watz H, Beeh KM, et al. COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition. Eur Respir J. 2020;56:2000237. doi:10.1183/13993003.00237-2020
   PubMed Web of Science ®Google Scholar
• Miller BE, Tal-Singer R, Rennard SI, et al. Plasma fibrinogen qualification as a drug development tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease biomarker qualification consortium. Am J Respir Crit Care Med. 2016;193:607–613.
   PubMed Web of Science ®Google Scholar
• Mannino DM. Biomarkers for chronic obstructive pulmonary disease diagnosis and progression: insights, disappointments and promise. Curr Opin Pulm Med. 2018.
   Web of Science ®Google Scholar
• Bellou V, Belbasis L, Konstantinidis AK, Tzoulaki I, Evangelou E. Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal. BMJ (Clinical Research Ed). 2019;367:l5358.
   PubMed Web of Science ®Google Scholar
• Peng J, Chen C, Zhou M, Xie X, Zhou Y, Luo CH. A machine-learning approach to forecast aggravation risk in patients with acute exacerbation of Chronic Obstructive Pulmonary Disease with clinical indicators. Sci Rep. 2020;10:3118. doi:10.1038/s41598-020-60042-1
   Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;192:523–525. doi:10.1164/rccm.201502-0235LE
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117–126. doi:10.1016/S2213-2600(18)30006-7
   PubMed Web of Science ®Google Scholar
• Karatas E, Bouchecareilh M. Alpha 1-antitrypsin deficiency: a disorder of proteostasis-mediated protein folding and trafficking pathways. Int J Mol Sci. 2020;21:1493. doi:10.3390/ijms21041493
   Web of Science ®Google Scholar
• Chorostowska-Wynimko J, Barrecheguren M, Ferrarotti I, Greulich T, Sandhaus RA, Campos M. New patient-centric approaches to the management of alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis. 2020;15:345–355. doi:10.2147/COPD.S234646
   PubMed Web of Science ®Google Scholar
• Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105:435–441. doi:10.1016/j.rmed.2010.09.006
   PubMed Web of Science ®Google Scholar